{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:42:11Z","timestamp":1792460531157,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100031146","name":"Harold Hamm Diabetes Center, OU Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031146","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015308","name":"Stephenson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM150970"],"award-info":[{"award-number":["R35GM150970"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007927","name":"University of Oklahoma Health Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007926","name":"The University of Oklahoma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.actbio.2025.05.066","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:16:45Z","timestamp":1748517405000},"page":"604-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Recombinant cytokine bioconjugates with degradable nanogel substrates for macrophage immunotherapy"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-6863","authenticated-orcid":false,"given":"Rana","family":"Ajeeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1919-5872","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Catelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-8735","authenticated-orcid":false,"given":"Harsh A.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Radyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-3041","authenticated-orcid":false,"given":"John R.","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nature Reviews Rheumatology"},{"issue":"4","key":"10.1016\/j.actbio.2025.05.066_bib0002","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"8","key":"10.1016\/j.actbio.2025.05.066_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202100035","article-title":"Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress","volume":"4","author":"Pires","year":"2021","journal-title":"Advanced Therapeutics"},{"issue":"15","key":"10.1016\/j.actbio.2025.05.066_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002214","article-title":"Engineered cytokines for cancer and autoimmune disease immunotherapy","volume":"10","author":"Uricoli","year":"2021","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"10.1016\/j.actbio.2025.05.066_bib0005","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"23","key":"10.1016\/j.actbio.2025.05.066_bib0006","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-22-1493","article-title":"Activation of adaptive and innate immune cells via localized IL2 cytokine factories eradicates mesothelioma tumors","volume":"28","author":"Nash","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.actbio.2025.05.066_bib0007","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.actbio.2025.05.066_bib0008","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41551-021-00831-9","article-title":"Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity","volume":"6","author":"Agarwal","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"16","key":"10.1016\/j.actbio.2025.05.066_bib0009","doi-asserted-by":"crossref","first-page":"eadk7695","DOI":"10.1126\/sciadv.adk7695","article-title":"Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity","volume":"10","author":"Niu","year":"2024","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.actbio.2025.05.066_bib0010","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","article-title":"Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets","volume":"5","author":"Hu","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"10.1016\/j.actbio.2025.05.066_bib0011","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nchembio.1096","article-title":"Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines","volume":"8","author":"Junttila","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.actbio.2025.05.066_bib0012","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.actbio.2025.05.066_bib0013","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.actbio.2025.05.066_bib0014","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1021\/acsnano.6b01114","article-title":"Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis","volume":"10","author":"Kamaly","year":"2016","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.actbio.2025.05.066_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10453","article-title":"Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors","volume":"8","author":"Barberio","year":"2023","journal-title":"Bioeng Transl Med"},{"issue":"2","key":"10.1016\/j.actbio.2025.05.066_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"issue":"4","key":"10.1016\/j.actbio.2025.05.066_bib0017","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","article-title":"Engineering cytokine therapeutics","volume":"1","author":"Deckers","year":"2023","journal-title":"Nature Reviews Bioengineering"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0018","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.actbio.2025.05.066_bib0019","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biomaterials.2015.04.003","article-title":"Paracrine co-delivery of TGF-\u03b2 and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells","volume":"59","author":"McHugh","year":"2015","journal-title":"Biomaterials"},{"issue":"20","key":"10.1016\/j.actbio.2025.05.066_bib0020","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.3390\/app10207098","article-title":"Nanotechnology Solutions for controlled cytokine delivery: an applied perspective","volume":"10","author":"Gon\u00e7alves","year":"2020","journal-title":"Applied Sciences"},{"issue":"10","key":"10.1016\/j.actbio.2025.05.066_bib0021","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.intimp.2011.05.014","article-title":"The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response","volume":"11","author":"Nicolete","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"16","key":"10.1016\/j.actbio.2025.05.066_bib0022","doi-asserted-by":"crossref","first-page":"9433","DOI":"10.1039\/D1RA00074H","article-title":"Cytotoxicity of targeted PLGA nanoparticles: a systematic review","volume":"11","author":"Chiu","year":"2021","journal-title":"RSC Adv"},{"issue":"10","key":"10.1016\/j.actbio.2025.05.066_bib0023","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.actbio.2025.05.066_bib0024","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/cplu.202000496","article-title":"Development of high-drug-loading nanoparticles","volume":"85","author":"Liu","year":"2020","journal-title":"ChemPlusChem"},{"issue":"3","key":"10.1016\/j.actbio.2025.05.066_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.actbio.2025.05.066_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114039","article-title":"Tailoring the physicochemical properties of nanomaterials for immunomodulation","volume":"180","author":"Deng","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.actbio.2025.05.066_bib0027","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2015.05.007","article-title":"Harnessing nanoparticles for immune modulation","volume":"36","author":"Getts","year":"2015","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.actbio.2025.05.066_bib0028","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1039\/D2CS00247G","article-title":"Bioengineered nanogels for cancer immunotherapy","volume":"51","author":"Ma","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"6","key":"10.1016\/j.actbio.2025.05.066_bib0029","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/jbm.a.36371","article-title":"Tunable poly(methacrylic acid-co-acrylamide) nanoparticles through inverse emulsion polymerization","volume":"106","author":"Zhong","year":"2018","journal-title":"J Biomed Mater Res A"},{"issue":"5","key":"10.1016\/j.actbio.2025.05.066_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202100127","article-title":"Nanoparticle internalization promotes the survival of primary macrophages","volume":"2","author":"Jarai","year":"2022","journal-title":"Adv Nanobiomed Res"},{"key":"10.1016\/j.actbio.2025.05.066_bib0031","series-title":"Bioconjugate Techniques","first-page":"549","article-title":"Chapter 14 - microparticles and nanoparticles","author":"Hermanson","year":"2013"},{"issue":"14","key":"10.1016\/j.actbio.2025.05.066_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201601240","article-title":"Metabolic reprogramming of macrophages exposed to silk, poly(lactic-co-glycolic acid), and silica nanoparticles","volume":"6","author":"Saborano","year":"2017","journal-title":"Adv Healthc Mater"},{"issue":"2","key":"10.1016\/j.actbio.2025.05.066_bib0033","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175445","article-title":"Modulation of macrophage metabolism as an emerging immunotherapy strategy for cancer","volume":"134","author":"Dussold","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.actbio.2025.05.066_bib0034","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2217\/nnm.12.111","article-title":"Complex encounters: nanoparticles in whole blood and their uptake into different types of white blood cells","volume":"8","author":"Baumann","year":"2013","journal-title":"Nanomedicine (Lond)"},{"issue":"7","key":"10.1016\/j.actbio.2025.05.066_bib0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/nano7070165","article-title":"Interleukin-10 conjugation to carboxylated PVP-coated silver nanoparticles for improved stability and therapeutic efficacy","volume":"7","author":"Baganizi","year":"2017","journal-title":"Nanomaterials"},{"issue":"3","key":"10.1016\/j.actbio.2025.05.066_bib0036","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41423-020-00541-3","article-title":"Macrophages and the maintenance of homeostasis","volume":"18","author":"Mosser","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0037","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"15","key":"10.1016\/j.actbio.2025.05.066_bib0038","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1042\/CS20220531","article-title":"M1\/M2 macrophages and their overlaps - myth or reality?","volume":"137","author":"Strizova","year":"2023","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0039","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ntno.30052","article-title":"Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment","volume":"3","author":"Reichel","year":"2019","journal-title":"Nanotheranostics"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/cells10010096","article-title":"Impact of gold nanoparticles on the functions of macrophages and dendritic cells","volume":"10","author":"Dey","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.actbio.2025.05.066_bib0041","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biomaterials.2016.01.064","article-title":"Carboxyl- and amino-functionalized polystyrene nanoparticles differentially affect the polarization profile of M1 and M2 macrophage subsets","volume":"85","author":"Fuchs","year":"2016","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.actbio.2025.05.066_bib0042","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1021\/nn402145t","article-title":"Dysregulation of macrophage activation profiles by engineered nanoparticles","volume":"7","author":"Kodali","year":"2013","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.actbio.2025.05.066_bib0043","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.4049\/jimmunol.1202102","article-title":"Shaping the murine macrophage phenotype: IL-4 and cyclic AMP synergistically activate the arginase I promoter","volume":"191","author":"Sheldon","year":"2013","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.actbio.2025.05.066_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21880","article-title":"Advantages and disadvantages of treatment of experimental ARDS by M2-polarized RAW 264.7 macrophages","volume":"9","author":"Kosyreva","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4049\/jimmunol.175.1.342","article-title":"Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences","volume":"175","author":"Stout","year":"2005","journal-title":"The Journal of Immunology"},{"issue":"9","key":"10.1016\/j.actbio.2025.05.066_bib0046","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/s12276-023-01068-z","article-title":"A new era of macrophage-based cell therapy","volume":"55","author":"Na","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.actbio.2025.05.066_bib0047","first-page":"379","article-title":"Synergy of interleukin-4 and interferon-\u03b3 in arginase-1 production in RAW264.7 macrophages","volume":"41","author":"Endo","year":"2023","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0048","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41467-020-20540-2","article-title":"Co-stimulation with opposing macrophage polarization cues leads to orthogonal secretion programs in individual cells","volume":"12","author":"Mu\u00f1oz-Rojas","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.actbio.2025.05.066_bib0049","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.4049\/jimmunol.171.10.5034","article-title":"Reprogramming of IL-10 activity and signaling by IFN-gamma","volume":"171","author":"Herrero","year":"2003","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.actbio.2025.05.066_bib0050","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1038\/s41467-019-11147-3","article-title":"IFN-\u03b3 selectively suppresses a subset of TLR4-activated genes and enhancers to potentiate macrophage activation","volume":"10","author":"Kang","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.actbio.2025.05.066_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112471","article-title":"The glycolysis\/HIF-1\u03b1 axis defines the inflammatory role of IL-4-primed macrophages","volume":"42","author":"Dang","year":"2023","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.actbio.2025.05.066_bib0052","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2009-08-236711","article-title":"Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion","volume":"115","author":"Varin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2025.05.066_bib0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","article-title":"Suppression of antigen presentation by IL-10","volume":"34","author":"Mittal","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"10.1016\/j.actbio.2025.05.066_bib0054","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1753425916668243","article-title":"Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli","volume":"22","author":"Chuang","year":"2016","journal-title":"Innate Immun"},{"issue":"12","key":"10.1016\/j.actbio.2025.05.066_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122606","article-title":"Cytokine therapy combined with nanomaterials participates in cancer immunotherapy","volume":"14","author":"Lian","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125004015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125004015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:28:22Z","timestamp":1776842902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125004015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":55,"alternative-id":["S1742706125004015"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.05.066","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant cytokine bioconjugates with degradable nanogel substrates for macrophage immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.05.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}